A detailed history of Two Sigma Investments, LP transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 634,441 shares of ARQT stock, worth $5.94 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
634,441
Previous 484,081 31.06%
Holding current value
$5.94 Million
Previous $4.8 Million 22.99%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$7.24 - $12.53 $1.09 Million - $1.88 Million
150,360 Added 31.06%
634,441 $5.9 Million
Q1 2024

May 15, 2024

SELL
$3.25 - $11.77 $1.61 Million - $5.82 Million
-494,724 Reduced 50.54%
484,081 $4.8 Million
Q4 2023

Feb 14, 2024

BUY
$1.84 - $4.82 $1.8 Million - $4.72 Million
978,805 New
978,805 $3.16 Million
Q4 2022

Feb 14, 2023

BUY
$13.96 - $20.4 $1.15 Million - $1.68 Million
82,528 Added 131.4%
145,336 $2.15 Million
Q3 2022

Nov 14, 2022

BUY
$17.85 - $26.95 $1.12 Million - $1.69 Million
62,808 New
62,808 $1.2 Million
Q2 2022

Aug 15, 2022

SELL
$16.33 - $22.2 $346,065 - $470,462
-21,192 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$14.38 - $22.79 $304,740 - $482,965
21,192 New
21,192 $408,000
Q3 2021

Nov 15, 2021

SELL
$19.28 - $27.1 $1.42 Million - $2 Million
-73,686 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$24.42 - $34.75 $955,359 - $1.36 Million
-39,122 Reduced 34.68%
73,686 $2.01 Million
Q1 2021

May 17, 2021

BUY
$24.47 - $36.98 $1.57 Million - $2.37 Million
63,978 Added 131.02%
112,808 $3.26 Million
Q4 2020

Feb 16, 2021

BUY
$17.82 - $31.73 $870,150 - $1.55 Million
48,830 New
48,830 $1.37 Million

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $563M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.